Publication:
The antifibrotic drug halofuginone reduces ischemia/reperfusion-induced oxidative renal damage in rats

Simple item page
dc.contributor.authorYEGEN, BERRAK
dc.contributor.authorsCerit, Kivilcim Karadeniz; Karakoyun, Berna; Yuksel, Meral; Ozkan, Naziye; Cetinel, Sule; Dagli, E. Tolga; Yegen, Berrak C.; Tugtepe, Halil
dc.date.accessioned2022-03-12T18:08:36Z
dc.date.available2022-03-12T18:08:36Z
dc.date.issued2013
dc.description.abstractAim: The objective of the present study was to evaluate the protective effects of halofuginone against renal ischemia/reperfusion (I/R) injury. Materials and methods: Male Wistar albino rats were unilaterally nephrectomized and the left renal pedicles were occluded for 45 min to induce ischemia and then reperfused for 6 h (early) or for 72 h (late). The rats were treated intraperitoneally with either halofuginone (100 mu g/kg/day) or saline 30 min prior to ischemia and the dose was repeated in the late reperfusion groups. In the sham groups, rats underwent unilateral nephrectomy and were treated at similar time points. The animals were decapitated at either 6 h or 72 h of reperfusion and trunk blood and kidney samples were obtained. Results: I/R injury increased renal malondialdehyde levels, myeloperoxidase activity and reactive oxygen radical levels, and decreased the renal glutathione content. Halofuginone treatment was found to reduce oxidative I/R injury and improve renal function in the rat kidney, as evidenced by reduced generation of reactive oxygen species, depressed lipid peroxidation and myeloperoxidase activity, and increased glutathione levels. Conclusions: The present findings demonstrate the anti-inflammatory and antioxidant effects of halofuginone in renal I/R injury, supporting its potential use where renal I/R injury is inevitable. (C) 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
dc.identifier.doi10.1016/j.jpurol.2012.01.015
dc.identifier.eissn1873-4898
dc.identifier.issn1477-5131
dc.identifier.pubmed22373656
dc.identifier.urihttps://hdl.handle.net/11424/231175
dc.identifier.wosWOS:000317837600017
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofJOURNAL OF PEDIATRIC UROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHalofuginone
dc.subjectIschemia/reperfusion
dc.subjectAcute renal injury
dc.subjectOxidant damage
dc.subjectRat
dc.subjectISCHEMIA-REPERFUSION INJURY
dc.subjectEXTRACELLULAR-MATRIX DEPOSITION
dc.subjectCOLLAGEN TYPE-1 SYNTHESIS
dc.subjectI SYNTHESIS
dc.subjectCOCCIDIOSTAT HALOFUGINONE
dc.subjectCELL-PROLIFERATION
dc.subjectINHIBITOR
dc.subjectFIBROSIS
dc.subjectMELATONIN
dc.subjectGROWTH
dc.titleThe antifibrotic drug halofuginone reduces ischemia/reperfusion-induced oxidative renal damage in rats
dc.typearticle
dspace.entity.typePublication
local.avesis.id8cb7b6d7-9cc1-4a22-9c39-607704b803c2
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages10
oaire.citation.endPage183
oaire.citation.issue2
oaire.citation.startPage174
oaire.citation.titleJOURNAL OF PEDIATRIC UROLOGY
oaire.citation.volume9
relation.isAuthorOfPublicatione4eaf9ac-f8dc-4e2b-b940-895cc906790d
relation.isAuthorOfPublication.latestForDiscoverye4eaf9ac-f8dc-4e2b-b940-895cc906790d

Files

Collections

Research Outputs